Hormone Receptor-positive Breast Cancer
📧 Sign up to get email alerts when something new happens for Hormone Receptor-positive Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer [Phase 2]
This is a Phase 2 clinical trial update for a combination of anastrozole, fulvestrant, and abemaciclib in HR-positive, HER2-negative metasta…
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer [Phase 2]
This clinical trial update describes a Phase II study evaluating HLX43 for efficacy and safety in patients with hormone receptor-positive, H…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib [Phase 2]
A Phase 2 pragmatic trial in hormone receptor-positive, HER2-negative early breast cancer is testing optimized neoadjuvant therapy and poten…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
A study led by Tempus AI is evaluating minimal residual disease in breast cancer by longitudinal ctDNA profiling to track disease status acr…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer [Phase 2]
This clinical trial update notes a single-arm Phase II study evaluating the combination of entinostat and oral paclitaxel for hormone recept…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment [Phase 3]
A Phase III clinical trial is evaluating capivasertib plus standard endocrine therapy in HR-positive, HER2-negative advanced breast cancer t…
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: Rash & Diarrhea Prophylaxis With Capivasertib [Phase 2]
Phase 2 clinical trial evaluating rash and diarrhea prophylaxis with capivasertib in metastatic hormone receptor-positive, HER2-negative bre…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors [Phase 1, Phase 2]
This is a Phase 1/2 clinical trial evaluating GVV858 as a single agent or in combination with endocrine therapy for hormone receptor-positiv…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating Efti in patients with hormone receptor-positive, HER2-negative breast cancer; not yet recruiting.
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer [Phase 2]
A Phase 2 clinical trial is evaluating radiation therapy combined with pembrolizumab and olaparib (or other radiosensitizers) in women with …
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer [Phase 1]
A Phase 1 clinical trial evaluating abemaciclib in combination with radiation therapy for metastatic breast cancer; the study is currently r…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer
A recruiting clinical trial evaluating how endocrine therapy, menstrual cycle phases, PAM50 subtype, and Ki67 influence treatment decisions …
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) [Phase 3]
A Phase 3 clinical trial update indicates Gedatolisib plus Fulvestrant, with or without Palbociclib, is active but not recruiting for advanc…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer [Phase 2]
Clinical trial update indicates a Phase 2 neoadjuvant study of iParomlimab and Tuvonralimab (QL1706) in hormone receptor-positive, HER2-nega…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Study of Screening Brain MRIs in Stage IV Breast Cancer
A clinical trial at H. Lee Moffitt Cancer Center is evaluating the use of screening brain MRIs in patients with Stage IV breast cancer, incl…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients
DiviTum TKa is being evaluated as a biomarker assay in a clinical trial for efficacy in HR-positive, HER2-negative metastatic breast cancer;…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer [Phase 3]
A Phase III trial evaluating NTQ1062 in combination with Fulvestrant for advanced or metastatic hormone receptor-positive/HER2-negative brea…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) [Phase 3]
A Phase 3 trial (VIKTORIA-2) is evaluating Gedatolisib as first-line therapy for HR-positive, HER2-negative advanced breast cancer and is cu…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer [NA]
This ClinicalTrials.gov entry indicates a study sponsored by Emory University to test Acutherapy for preventing aromatase inhibitor–associat…
-
CLINICAL_TRIALS research · 2026-01-26Clinical Trial Update: CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment [Phase 2]
A Phase 2 neoadjuvant trial is evaluating CDK4/6 inhibitors combined with endocrine therapy for hormone receptor-positive breast cancer; the…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 [Phase 1]
Phase 1 study assessing adverse events and change in disease activity in adults with select advanced solid tumors treated with ABBV-400; the…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer [Phase 2]
Phase 2 trial evaluating the combination of olaparib and pembrolizumab in triple-negative breast cancer and hormone receptor-positive, HER2-…
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: RWE About QOL and Compliance of Patients With OFS in China
A completed clinical trial provides real-world evidence on quality of life and adherence among patients treated with ovarian function suppre…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
This ClinicalTrials.gov entry describes a prospective registry evaluating an antibody-drug conjugate as first- and second-line therapy for b…
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer [Phase 3]
A Phase 3 clinical trial evaluating SKB264 for locally advanced, recurrent or metastatic HR+/HER2- breast cancer is currently recruiting.